Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

OBE2109 potential best in class based upon dosing options     OBE2109 ELAGOLIX*RELUGOLIX* Moderate dose withoutABT Moderate dose without ABT (150mg)High dose with ABT (40mg) EndometriosisHigh dose with ABTHigh dose with ABT (200mg bid)same dose 3 months only w/o ABT Moderate dose without ABTHigh dose with ABT (40mg) Uterine FibroidsHigh dose with ABT(300mg bid) High dose with ABTsame dose 3 months only w/o ABT Treatment durationPlacebo control for 12 monthsPlacebo control for 6/12 monthsPlacebo control for 6 months